Our latest Investing Matters Podcast episode with QuotedData's Edward Marten has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFusion Antibody Regulatory News (FAB)

Share Price Information for Fusion Antibody (FAB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.75
Bid: 3.70
Ask: 3.80
Change: -0.10 (-2.60%)
Spread: 0.10 (2.703%)
Open: 3.85
High: 3.85
Low: 3.75
Prev. Close: 3.85
FAB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Half year trading update

22 Oct 2019 07:00

RNS Number : 6162Q
Fusion Antibodies PLC
22 October 2019
 

 

Fusion Antibodies plc

("Fusion" or the "Company")

 

Half year trading update

 

Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, provides a business and unaudited trading update for the six months ended 30 September 2019 ("H1 FY2020"), confirming continued revenue growth and the commercial roll out of new services.

 

Operational highlights

·; Increase in orders and revenues in H1 FY2020 over H2 FY2019

·; First commercial projects for customers of the new Rational Affinity Maturation Platform ("RAMPTM") service

·; Continuing development of Mammalian Antibody Library for delivery in 2020

 

Financial highlights

·; Continued improvement in revenues for H1 FY2020 of £1.7m (H1 FY2019: £0.7m; H2 FY2019: £1.5m)

·; Trading for the year ending 31 March 2020 to date has been in line with market expectations

·; Additional results-dependent customer milestones agreed

·; Cash position at 30 September 2019 was £1.3m (31 March 2019: £2.0m)

 

Business update

The growth in revenues and orders seen in H2 FY2019 continued in H1 FY2020 with unaudited revenues of £1.7m, resulting in the Company's strongest six month period to date.

 

This continued improvement includes the first commercial revenues from RAMPTM, augmented by the expansion of the laboratory capacity and increased business development and marketing efforts as previously announced.

 

RAMPTM is the innovative service designed to provide customers with improvements to antibody affinity and reduce of other unwanted characteristics. This service is available either as part of the suite of Fusion services or as a stand-alone service to companies with existing antibodies with sub-optimal performance. In the period we received our first revenues from early adopters of RAMPTM. Initial results from these customers are very promising and the full commercial roll out of the service will continue throughout the remainder of the year, with presentations at scientific conferences and targeted marketing.

 

The Company is able to fulfil the majority of orders received with a short turnaround which reduces the visibility of future earnings. However, the Directors continue to be confident that growth in order levels for existing and new services will continue.

 

The Company principally charges for its services on a fee for service basis and in certain cases has an additional royalty or results-dependent milestone based on progress of the customer's project into clinical trials or commercialisation. The Company has continued to add to its portfolio of milestones in H1 FY2020. The Company has not recognised any such revenues from the portfolio in H1 FY2020 and does not factor in these potential milestone revenues in its growth expectations, due to the reliance on customers to progress projects to the point where such revenues are triggered and therefore the uncertainty over the potential timings or realization of any such revenues.

 

Investor presentation at ShareSoc

 

The Company will be presenting at a ShareSoc meeting in London on Wednesday 13 November 2019. If you wish to attend, please register at https://www.sharesoc.org/events/ 

 

Paul Kerr, CEO of Fusion Antibodies plc, commented: We continued to see good revenue growth during this first six months and have had a strong improvement in the previous six months. We are continuing the rollout of RAMPTM, which has been well received, and are on track to deliver our Mammalian Antibody Library in 2020 as planned. We remain confident of an encouraging second half and that the Company will achieve significant revenue growth for the full year. I would like to thank our shareholders for their valued support and I look forward to updating the market further when we announce our interim results later in the year."

 

Enquiries:

 

Fusion Antibodies plc

www.fusionantibodies.com

Dr Paul Kerr, Chief Executive Officer

Via Walbrook PR

James Fair, Chief Financial Officer

 

Allenby Capital Limited

Tel: +44 (0)20 3328 5656

James Reeve / Asha Chotai

 

Walbrook PR

Tel: +44 (0)20 7933 8780 or fusion@walbrookpr.com

Anna Dunphy

Mob: +44 (0)7876 741 001

Paul McManus

Mob: +44 (0)7980 541 893

 

About Fusion Antibodies plc

 

Fusion is a Belfast based contract research organisation ("CRO") providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.

 

The Company's ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion's proprietary CDRxTM platform and the production of antibody generating stable cell lines to provide material for use in clinical trials. Since 2012, the Company has successfully sequenced and expressed over 250 antibodies and successfully completed over 150 humanisation projects for its international, blue-chip client base, which has included eight of the top 10 global pharmaceutical companies by revenue.

 

The Company was established in 2001 as a spin out from Queen's University Belfast. The Company's mission is to enable pharmaceutical and diagnostic companies to develop innovative products in a timely and cost-effective manner for the benefit of the global healthcare industry. Fusion Antibodies provides a broad range of services in antibody generation, development, production, characterisation and optimisation.

Fusion Antibodies growth strategy is based on combining the latest technological advances with cutting edge science to deliver new platforms that will enable Pharma and Biotechs get to the clinic faster and ultimately speed up the drug development process.

 

The global monoclonal antibody therapeutics market was valued at $95.5 billion in 2017 and is forecast to surpass $174.2 billion in 2026, an increase at a CAGR of between 6.9 per cent. for the period 2018 to 2026. In 2018, seven of the world's ten top selling drugs were antibody-based therapeutics with the combined annual sales of these drugs exceeding $62 billion.  

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTUAANRKNARUAA
Date   Source Headline
28th Mar 20245:00 pmRNSTotal Voting Rights
11th Mar 20243:04 pmRNSHolding(s) in Company
11th Mar 20249:10 amRNSHolding(s) in Company
8th Mar 20243:09 pmRNSHolding(s) in Company
5th Mar 202410:40 amRNSResult of General Meeting and Total Voting Rights
29th Feb 20245:00 pmRNSTotal Voting Rights
27th Feb 20247:00 amRNSFirst purchase order under MSA
14th Feb 20247:15 amRNSGrant of options and issue of shares to directors
14th Feb 20247:00 amRNSPlacing to raise £1,375,000
6th Feb 20247:00 amRNSFollow-on project award and R&D update
1st Feb 20247:00 amRNSHMRC R&D tax credit
4th Dec 202312:26 pmRNSDirector/PDMR Shareholding
4th Dec 20237:00 amRNSHalf-year Report
28th Nov 20237:00 amRNSOptiMAL collaboration agreement
9th Nov 20237:00 amRNSHalf year trading update
27th Oct 202311:57 amRNSResult of AGM
4th Oct 20232:45 pmRNSBlock admission six monthly return
29th Sep 20237:00 amRNSFinal Results
29th Aug 20237:00 amRNSUpdate on AI/ML-Ab service offering
24th Aug 20237:00 amRNSAppointment of interim CFO
21st Aug 20237:00 amRNSUpdate on AI/ML-Ab™ antibody discovery service
14th Aug 20237:00 amRNSUpdate on restructure and cost savings
30th Jun 20235:00 pmRNSTotal Voting Rights
16th Jun 202310:09 amRNSHolding(s) in Company
15th Jun 20239:45 amRNSHolding(s) in Company
13th Jun 20232:44 pmRNSHolding(s) in Company
12th Jun 20233:34 pmRNSHolding(s) in Company
12th Jun 202311:02 amRNSDirector/PDMR Shareholding
8th Jun 202310:39 amRNSResult of GM and total voting rights
31st May 20235:00 pmRNSTotal Voting Rights
26th May 20234:57 pmRNSHolding(s) in Company
26th May 20231:33 pmRNSHolding(s) in Company
23rd May 20237:00 amRNSResult of Retail Offer and Notice of GM
19th May 202310:01 amRNSREX Retail Offer
19th May 202310:00 amRNSPlacing, Subscription and Retail Offer
3rd Apr 20237:00 amRNSBlock listing Interim Review
31st Mar 20237:00 amRNSChange of Registered Office
21st Mar 20237:00 amRNSPatent application
6th Mar 202311:05 amRNSSecond Price Monitoring Extn
6th Mar 202311:00 amRNSPrice Monitoring Extension
6th Mar 20237:00 amRNSTrading Statement
9th Feb 20237:00 amRNSR&D update: Mammalian Display service
9th Jan 20234:40 pmRNSSecond Price Monitoring Extn
9th Jan 20234:35 pmRNSPrice Monitoring Extension
9th Jan 20232:05 pmRNSSecond Price Monitoring Extn
9th Jan 20232:00 pmRNSPrice Monitoring Extension
9th Jan 202311:05 amRNSSecond Price Monitoring Extn
9th Jan 202311:00 amRNSPrice Monitoring Extension
5th Dec 20227:00 amRNSHalf-year Report
24th Nov 20227:00 amRNSNotice of Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.